travellinglight/iStock via Getty Images
Cassava Sciences (NASDAQ:SAVA) reported better-than-expected earnings with its Q3 2024 financials on Thursday and reaffirmed its timeline to deliver a key Phase 3 readout for its oral Alzheimer’s candidate simufilam before the year-end.
SAVA’s Phase 3 program for simufilam comprises